Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Use of Exogenous Progestins and Risk of In Situ and Invasive Breast Cancer
Not an EDRN Protocol

Use of Exogenous Progestins and Risk of In Situ and Invasive Breast Cancer

1036

No involved investigator sites defined.

The SHARE II Study (Seattle Area Hormone And Reproductive Epidemiology Breast Cancer Study) is a 6 year grant funded by the Breast Cancer Research Program of the U.S. Department of Defense, to continue the SHARE Study. This is a population-based case-control study, which investigates how menopausal hormone therapy use and other known breast cancer risk factors are related to the risks of invasive lobular, ductal and mixed ductal-lobular carcinomas. Given the rapid increases in lobular, and particularly ductal-lobular, incidence rates, the epidemiologic data suggesting that certain risk factors differ considerably in their associations with lobular vs. ductal tumors (but that require confirmation and enhancement), the differences in these tumors’ molecular features that may reflect differing etiologic pathways, and the more recently emerging data indicating important differences between invasive pure lobular carcinomas (IPLC) and invasive ductal-lobular carcinomas (IDLC), it is clear that distinguishing between different histologic types in observational studies is an important, though underutilized, strategy for gaining insights into breast cancer etiology. To address the need for studies that further our knowledge of IPLC and IDLC, we propose to extend our existing population-based case-control study that enrolled 469 controls, 271 IPLC cases, 330 IDLC, and 442 IDC (invasive ductal carcinoma) cases, with an additional 325 subjects in each of these groups. When the two studies are combined, there will be 794 controls, 596 IPLC, 655 IDLC, and 767 IDC cases. With the addition of more cases we will have sufficient statistical power to address the following new questions: 1. How do known breast cancer risk factors, such as reproductive factors, anthropometric measures, alcohol use, and family history of breast cancer, modify the associations between use of different hormone therapy regimens and risks of lobular, ductal-lobular, and ductal carcinomas? 2. How are known breast cancer risk factors, including reproductive factors, anthropometric measures, alcohol use, and family history of breast cancer, related to risks of lobular, ductal-lobular, and ductal carcinomas, and how do breast cancer risk factors interact with each other to alter these risks? 3. How do ductal-lobular carcinomas differ from lobular and ductal carcinomas in their expression of ER, PR, c-erbB-2, e-cadherin, and Ki-67? 4. How do known breast cancer risk factors, and CHT use in particular, influence the expression of ER, PR, c-erbB-2, e-cadherin, Ki-67, in lobular, ductal-lobular, and ductal carcinomas?

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.